- Home
- AFL vs TAK Comparison
AFL vs TAK Comparison
Compare AFL & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFL
- TAK
- Stock Information
- Founded
- AFL 1955
- TAK 1781
- Country
- AFL United States
- TAK Japan
- Employees
- AFL N/A
- TAK N/A
- Industry
- AFL Accident &Health Insurance
- TAK Biotechnology: Pharmaceutical Preparations
- Sector
- AFL Finance
- TAK Health Care
- Exchange
- AFL Nasdaq
- TAK Nasdaq
- Market Cap
- AFL 57.1B
- TAK 45.8B
- IPO Year
- AFL N/A
- TAK N/A
- Fundamental
- Price
- AFL $103.30
- TAK $14.76
- Analyst Decision
- AFL Hold
- TAK
- Analyst Count
- AFL 15
- TAK 0
- Target Price
- AFL $105.00
- TAK N/A
- AVG Volume (30 Days)
- AFL 2.0M
- TAK 1.9M
- Earning Date
- AFL 07-30-2025
- TAK 07-30-2025
- Dividend Yield
- AFL 2.25%
- TAK 4.01%
- EPS Growth
- AFL N/A
- TAK N/A
- EPS
- AFL 6.44
- TAK 0.45
- Revenue
- AFL $16,889,000,000.00
- TAK $30,595,075,281.00
- Revenue This Year
- AFL N/A
- TAK $1.01
- Revenue Next Year
- AFL $0.77
- TAK $1.04
- P/E Ratio
- AFL $15.98
- TAK $63.71
- Revenue Growth
- AFL N/A
- TAK 7.45
- 52 Week Low
- AFL $88.00
- TAK $12.58
- 52 Week High
- AFL $115.50
- TAK $15.43
- Technical
- Relative Strength Index (RSI)
- AFL 49.17
- TAK 46.62
- Support Level
- AFL $101.41
- TAK $14.86
- Resistance Level
- AFL $103.28
- TAK $15.42
- Average True Range (ATR)
- AFL 1.70
- TAK 0.14
- MACD
- AFL 0.16
- TAK -0.03
- Stochastic Oscillator
- AFL 74.40
- TAK 9.47
About AFL AFLAC Incorporated
Aflac Inc offers supplemental health insurance and life insurance in the United States and Japan. In addition to its cancer policies, the company has broadened its product offerings to include accident, dental and vision, disability, and long-term-care insurance. It markets its products through independent distributors, selling the majority of its policies directly to consumers at their places of work, and also reaches out to its customers outside of their worksite through digital mediums. The company has two reportable business segments; Aflac Japan which generates the majority of the revenue, and Aflac U.S.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.